Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Pascal

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bulletin Du Cancer|July 28, 2023
[Creating a community of heads of department to meet hospital system challenges: First experience in haematology]Roch Houot, Jacques-Olivier Bay, Patrice Chevallier, et al.
Blood|July 11, 2015
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantationLaurent Pascal, Luciana Tucunduva, Annalisa Ruggeri, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
Cancer Medicine|February 24, 2018
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studiesAurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Clinical and Experimental Medicine|August 11, 2022
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseasesVincent Jachiet, Laure Ricard, Pierre Hirsch, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
American Journal of Hematology|April 2, 2024
Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO studyMatthieu Groh, Laurène Fenwarth, Mathilde Labro, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bulletin Du Cancer|July 28, 2023
[Creating a community of heads of department to meet hospital system challenges: First experience in haematology]Roch Houot, Jacques-Olivier Bay, Patrice Chevallier, et al.
Blood|July 11, 2015
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantationLaurent Pascal, Luciana Tucunduva, Annalisa Ruggeri, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
Cancer Medicine|February 24, 2018
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studiesAurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Clinical and Experimental Medicine|August 11, 2022
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseasesVincent Jachiet, Laure Ricard, Pierre Hirsch, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
American Journal of Hematology|April 2, 2024
Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO studyMatthieu Groh, Laurène Fenwarth, Mathilde Labro, et al.
Pageof 2